Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

Yeah, I'm not sure about the specificity as a general screen either. We'll have to wait for further testing that directly tests that. For now we are going off of the FDA document for the CRC progression which had specific guidelines that basically adapted the test for that purpose. Other than that, we have the FDP levels from that same FDA document. Those showed promise for specific cancers and diseases but refinement is certainly needed.